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1. Introduction 
Disturbances of cognitive function, evaluated by psychological and neurophysiological 
methods, have been shown to predict outcome in patients with schizophrenia (Green et al. 
2000, Javitt et al. 2008, Sumiyoshi T. et al. 2011). In view of the paucity of treatment options 
to improve cognition for these patients, efforts to identify novel strategies are needed. 
The prefrontal cortex (PFC) has been considered to regulate various aspects of cognitive 
abilities, e.g. working memory, memory organization, executive function, and attention 
(Sumiyoshi T. et al. 2011). Atypical antipsychotic drugs (AAPDs), eliciting cognitive 
benefits to some extent, enhance dopamine (DA) release in the medial PFC (mPFC), as 
demonstrated by in vivo microdialysis (Bortolozzi et al. 2010, Diaz-Mataix et al. 2005, 
Ichikawa et al. 2001). The ability of AAPDs to enhance DA in mPFC has been found to 
depend on serotonin (5-HT)-5-HT1A receptors, irrespective of direct in vitro affinity, based 
on observations from mutant mice lacking these receptors (Bortolozzi et al. 2010, Diaz-
Mataix et al. 2005). This is consistent with behavioral observations that 5-HT1A partial 
agonists (e.g. tandospirone) and AAPDs with agonist actions on 5-HT1A receptors (e.g. 
perospirone, aripiprazole, ziprasidone, lurasidone) ameliorate memory deficits in rodent 
models of schizophrenia (Hagiwara et al. 2008, Horiguchi et al. in press, Meltzer et al. 
2011, Nagai et al. 2009). Findings from electrophysiological studies suggest these 
cognitive benefits of 5-HT1A agonism are mediated by glutamate (Glu) and γ-
aminobutyric acid (GABA) neurons (Higuchi et al. 2010, Llado-Pelfort et al. 2011). 
In this chapter, the authors discuss the role for the key 5-HT receptor subtypes, i.e., 5-HT1A, 
5-HT2A, 5-HT6, and 5-HT7 receptors, in cognitive function in schizophrenia. Specifically, we 
will focus on several psychotropic/antipsychotic compounds stimulating 5-HT1A receptors, 
considered as one of the most promising candidates for cognitive enhancers (Meltzer et al. 
2011, Newman-Tancredi and Kleven 2011, Newman-Tancredi and Albert in press). A 
hypothesis is presented on the relationship between cognition and lactate that provides an 
important energy substrate and reflects neural activity in the brain. 
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2. Neurocognitive deficits of schizophrenia 
Schizophrenia has been characterized by positive symptoms (e.g. delusions, hallucinations 
and thought disorder) and negative symptoms (e.g. psychomotor retardation, affective 
flattening, social withdrawal, and alogia). Patients with the illness also exhibit a wide range 
of disturbances of cognitive function, including several types of memory, executive function 
(e.g. planning, monitoring, inhibition), vigilance, motor speed, and verbal fluency, with 
more than 1SD below the average of normal controls (Harvey and Keefe 1997).  
Generally, they are considered to be independent of the psychotic symptoms. The cognitive 
deficits of schizophrenia have been investigated extensively as a determinant of functional 
outcome (Addington and Addington 2000, Green 1996, Green et al. 2000). 
Several instruments to comprehensively assess cognitive function in schizophrenia have 
been developed. In particular, the Measurement and Treatment Research to Improve 
Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (Nuechterlein et al. 
2008) (Fig 1) and the Brief Assessment of Cognition in Schizophrenia (BACS) (Keefe et al. 
2004) (Fig 2) are regarded to be qualified as international-standard neuropsychological tools 
in this respect. The authors have developed the Japanese versions of these cognitive test 
batteries (Kaneda et al. 2007, Sato et al. 2010), and have confirmed their sensitivity and 
validity to detect cognitive deficits in patients (Fig 3).  
 
Fig. 1. Examples of tests from the MATRICS Consensus Cognitive Battery. 
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Fig. 2. Examples of tests from the Brief Assessment of Cognition in Schizophrenia.  
 
Fig. 3. Impaired cognitive function in schizophrenia as evaluated by the Brief Assessment of 
Cognition in Schizophrenia -Japanese Version (Kaneda et al. 2007). 
3. 5-HT receptors and cognitive function 
The role for several subtypes of 5-HT receptors in cognitive function has attracted interest, 
based, partly, on the distinct pharmacological properties of AAPDs, such as clozapine, 
risperidone, and olanzapine. For example, the ability of these agents to enhance DA and 
acetylcholine release in the mPFC, demonstrated by in vivo microdialysis, has been reported 
(Bortolozzi et al. 2010, Diaz-Mataix et al. 2005, Ichikawa et al. 2002, Ichikawa et al. 2001). 
Among the subtypes of 5-HT receptors (Fig. 4), 5-HT1A, 5-HT2A, 5-HT6, and 5-HT7 receptors 
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have been shown to be associated with cognitive effects of AAPDs, suggesting pivotal roles 
for the serotonergic system in cognitive symptoms of schizophrenia (Sumiyoshi T. et al. 
2007a, Meltzer and Sumiyoshi 2008, Sumiyoshi T. et al. 2008).  
 
Fig. 4. Chemical structure of serotonin (5-HT) and its receptor subtypes. 
Table 1. summarizes the mode of actions (agonism or antagonism) and specific compounds 
related to the above-mentioned 5-HT receptor subtypes. Among them, 5-HT1A receptor 
stimulation is currently considered as the most promising approach (Llado-Pelfort et al. 
2011, Newman-Tancredi and Kleven 2011, Newman-Tancredi and Albert in press, 
Sumiyoshi C. et al. 2006, Sumiyoshi T. et al. 2008, Sumiyoshi T. et al. 2007a, Sumiyoshi T. et 
al. 2000, Sumiyoshi T. et al. 2007b, Sumiyoshi T. et al. 2001a, Sumiyoshi T. et al. 2001b, 
Sumiyoshi T. et al. 2009), as discussed in the next section. This is followed by 5-HT2A 
antagonism, as elicited by certain (although not satisfactory) efficacy of a series of AAPDs 
whose principal pharmacologic feature is blockade of 5-HT2A receptors (Meltzer et al. 1989, 
Meltzer et al. 2011, Meltzer and Massey 2011, Stockmeier et al. 1993, Sumiyoshi T. et al. 
1995). Recent evidence from animal models of schizophrenia suggests the advantage of 
agonists at 5-HT6 or 5-HT7 receptors for ameliorating memory impairment, as revealed by 
behavioral experiments using antagonist at the N-methyl-D-aspartate (NMDA) type of Glu 
receptors (Horiguchi et al. 2011, Meltzer et al. 2011, Meltzer and Massey 2011).  
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5-HT subtypes Mode of Compounds
actions
5-HT1A (partial) agonist tandospirone, buspirone
F15599, ziprasidone
aripiprazole, perospirone
lurasidone
5-HT2A antagonist clozapine, risperidone
olanzapine, perospirone
quetiapine, melperone
N-desmethylclozapine
5-HT6 antagonist Ro04-6790
Lu AE58054
5-HT7 antagonist SB25874
amisulpiride
lurasidone
 
Ref) Harvey et al. 2011; Kern et al. 2006; Llado-Pelfort et al. 2010, 2011;  
Meltzer et al. 2011; Meltzer and Massey 2011; Newman-Tancredi 2011, in press;  
Sumiyoshi et al. 2000, 2001a, 2001b, 2006, 2007a, 2007b, 2008, 2009 
Table 1. Serotonin (5-HT) receptors in the treatment of cognitive disturbances. 
4. Role for 5-HT1A stimulation in cognitive enhancement 
The interest in the 5-HT1A receptor in relation to cognition in schizophrenia was founded by a 
series of pilot studies of the effects of augmentation therapy with tandospirone, a 5-HT1A 
partial agonist, in patients treated with antipsychotic drugs (Sumiyoshi T. et al. 2000, 
Sumiyoshi T. et al. 2001a, Sumiyoshi T. et al. 2001b). The addition of tandospirone (30 
mg/day), but not placebo, to typical antipsychotic drugs (mainly haloperidol) for 4–6 weeks, 
was found to improve verbal memory (effect size = 0.70), memory organization, and executive 
function (0.63) (Sumiyoshi T. et al. 2000, Sumiyoshi T. et al. 2001a, Sumiyoshi T. et al. 2001b).  
The beneficial effect of augmentation therapy with 5-HT1A agonists in schizophrenia was 
further supported by a randomly assigned placebo-controlled double-blind study with 
buspirone, another 5-HT1A partial agonist (Sumiyoshi T. et al. 2007a). Patients with 
schizophrenia, who had been treated with an atypical antipsychotic drug, were assigned to 
receive either buspirone, 30 mg/day, or matching placebo for 6 months. Buspirone 
outperformed placebo in improving the performance on a measure of attention/speeded 
motor performance (effect size = 0.32), indicating an advantage for cognitive abilities 
regulated by prefrontal cortex, as in the case of tandospirone. Evidence from these proof-of-
concept studies has prompted the recent endeavor to develop cognition-enhancing drugs 
with 5-HT1A agonist actions (Depoortere et al. 2010, Llado-Pelfort et al. 2010, Llado-Pelfort et 
al. 2011, Newman-Tancredi 2010, Newman-Tancredi and Kleven 2011, Newman-Tancredi and 
Albert in press). Some of the compounds so far synthesized in this line are shown in Fig 5. 
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Fig. 5. Some of the psychotropic/antipsychotic compounds with agonist actions on 5-HT1A 
receptors. 
Support for this therapeutic strategy comes from animal data suggesting 5-HT1A partial 
agonists (e.g. tandospirone) and AAPDs with agonist actions on 5-HT1A receptors (e.g. 
perospirone, aripiprazole, ziprasidone, lurasidone) ameliorate memory deficits due to 
NMDA receptor blockade (Hagiwara et al. 2008, Horiguchi et al. 2011, Horiguchi et al. in 
press, Meltzer et al. 2011, Nagai et al. 2009). The ability of these compounds to improve 
cognition has been related to enhancement of extracellular concentration of DA in the PFC 
(Bortolozzi et al. 2010, Diaz-Mataix et al. 2005, Ichikawa et al. 2001, Yoshino et al. 2004), an 
effect which is absent in mutant mice lacking 5-HT1A (Bortolozzi et al. 2010, Diaz-Mataix et 
al. 2005), but not 5-HT2A (Bortolozzi et al. 2010) receptors.  
As illustrated in Fig. 6, Glu, GABA, 5-HT, and DA neurons constitute a network in the PFC 
that regulates several domains of cognition, e.g. some types of memory, executive function 
and attention. Among the variety of relevant receptors in this neural cascade, 5-HT1A 
receptors are located on Glu (pyramidal) and GABA neurons. Excitation of pyramidal 
neurons projecting to ventral tegmental area enhances mesocortical DA function, leading to 
amelioration of negative and cognitive symptoms of schizophrenia (Llado-Pelfort et al. 2010, 
Llado-Pelfort et al. 2011). Specifically, systemic administration of 8-OH-DPAT, a 
prototypical 5-HT1A agonist, to rats increased the discharge rate of pyramidal neurons in 
mPFC, by inhibiting fast-spiking GABAergic interneurons through a preferential action on 
5-HT1A receptors on these latter neurons (Llado-Pelfort et al. 2011). This finding reconciles 
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the observations that endogenous 5-HT inhibits pyramidal neurons in mPFC, while systemic 
administration of 5-HT1A agonists excites them. These considerations are consistent with the 
clinical observation that augmentation therapy with tandospirone enhanced mismatch 
negativity, an electrophysiological cognitive marker of Glu neuron activity, in schizophrenia 
(Higuchi et al. 2010). 
 
Fig. 6. Neural network in the prefrontal cortex involving glutamate, GABA, 5-HT and DA 
neurons. Part of the effect of 5-HT1A agonists on cognition and negative symptoms is 
thought to be mediated by 5-HT1A receptors located on GABAergic interneurons regulating 
glutamatergic pyramidal neurons. VTA, ventral tegmental area. 
5. Lactate in brain energy metabolism  
Although glucose has been considered to be a major supplier of energy in the brain, recent 
investigations report that lactate also plays a significant role in energy metabolism, 
especially during acute neural activation (Aubert et al. 2005, O'Brien et al. 2007). According 
to the “astrocyte-neuron lactate shuttle hypothesis” (Laughton et al. 2007, Pellerin 2003), 
lactate is produced in a neural activity-dependent and glutamate-mediated manner by 
astrocytes, and is transferred to and used by active neurons (reviewed in Uehara et al. 2008) 
(Fig. 7). Data from a recent study (Wyss et al. 2011) suggest that the brain prefers lactate 
over glucose as an energy substrate when both are available, and that lactate exerts a direct 
neuroprotective effect. 
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Fig. 7. Enhancement of lactate production by glutamatergic transmission. GluT1, glutamate 
transporter; NMDA-R, N-methyl-D-aspartate receptor. (Uehara et al. Pharmacol Biochem 
Behav 90:273, 2008) 
6. Role for 5-HT1A agonism in lactate production in an animal model of 
schizophrenia  
Rats administered MK-801 on postnatal days (PD) 7-10 have been shown to elicit 
impairment of set-shifting test, a measure of prefrontal cortex function, in early adulthood 
(Stefani and Moghaddam 2005). The same model animals elicit disruption of prepulse 
inhibition, a measure of sensorimotor gating (Uehara et al. 2009, Uehara et al. 2010) and 
enhancement of spontaneous and metamphetamine-induced locomotor activity (Uehara 
et al. 2010) after, but not before puberty (Table 2). These findings suggest that transient 
blockade of NMDA receptors at the neonatal stage produces cognitive abnormalities in 
rodent models of schizophrenia based on the neurodevelopmental hypothesis of the 
illness. 
Lactate metabolism in mPFC has been shown to be modulated by 5-HT1A receptors both 
during resting condition and acute neural activation. In particular, acute administration of 
tandospirone led to a significant increase in extracellular lactate concentrations, and reduced 
the footshock stress-induced lactate increment in the mPFC in rats (Uehara et al. 2006). 
Taken together, it was hypothesized that transient blockade of NMDA receptors during the 
neonatal stage (modeling schizophrenia) would inhibit energy demands in response to 
stress in the mPFC at the young adult stage, and that 5-HT1A partial agonist, such as 
tandospirone, would reverse the effect of the neonatal insult on energy metabolism.  
Female Wistar rats obtained at 14 days of pregnancy. At postnatal (PD) day 7 (PD7), male 
pups were randomly divided into two groups. They received MK-801 (dizocilpine), or an 
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equal volume of saline (control; vehicle group) once daily for 4 days. At the time of weaning 
on PD 21, the pups were grouped into four to six per treatment. 
35 637-10
MK-801
Puberty
Prepulse
inhibition
N.C. decreased
Spontaneous 
locomotion
MAP-induced 
locomotion
N.C.
N.C.
Postnatal 
days
 
Transient blockade of NMDA receptors by MK-801 at the neonatal stage produces disruption of 
prepulse inhibition, as well as spontaneous or methamphetamine (MAP)-induced hyperlocomotion 
after, but not before puberty. 
N.C., no change. 
Table 2. Behavioral changes in a rat model of schizophrenia based on the 
neurodevelopmental hypothesis. 
On PD49, animals were assigned to receive either saline or tandospirone at 1.0 mg/kg, (s.c.). 
This yielded the following groups: saline-saline group, saline-tandospirone group, MK801-
saline group, and MK801-tandospirone group. For 14 days before the microdialysis 
examination, saline or tandospirone was administered (s.c.) once daily. Microdialysis was 
performed 24 hours after the last injection. 
Microdialysis experiments were performed on PD63. Forty-two to 48 hr before microdialysis 
experiments, the animals were anesthetized, and were mounted on a stereotaxic apparatus. 
A dialysis probe was implanted into the left mPFC with the coordinates of A 3.2mm, L 
0.6mm, V 5.2mm from bregma. The dialysis experiment was carried out on the freely 
moving rats. Artificial CSF was perfused into the dialysis probe. The dialysates were mixed 
on-line with an enzyme solution containing L-lactate dehydrogenate and NAD+ in a T-tube. 
During transport of the mixture to the fluorometer, lactate was enzymatically oxidized and 
the fluorescence of the nicotinamid adenosine dinucleotide diphosphate (NADH) formed 
was continuously measured, with a standard solution of 100 μmol/L lactate for calibration. 
Footshock stress was administered using a plastic communication box, according to the 
method described previously (Uehara et al., 2006). The box (L 51cm x W 51cm x H 40cm) 
was equipped with a grid floor, and was subdivided into nine compartments (17cm x17cm) 
by transparent plastic walls. In this study, we used 4 compartments area (34cm x 34cm) for 
the field of free moving and footshock administration. The communication box was 
connected to a shock-generator to deliver footshocks as described below. Each footshock 
session consisted of a scramble shock of 0.3 mA for 5 seconds administered every 30 seconds 
for 10 minutes. After the experimental sessions, the position of dialysis probes was verified 
by dissection of the brain. 
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Data were analyzed by analysis of variance (ANOVA). The average of extracellular lactate 
concentrations during the period preceding the start of footshock stress (ten measurements 
performed every 2 min) was used as the control value (100 %). Data from tandospirone 
administration experiments were analyzed using three-way repeated measures ANOVA; 
Status and Drug were treated as between-group variables. Time was treated as a repeated 
measures variable.  
As expected, transient neonatal administration of MK-801 suppressed lactate increment in 
response to footshock stress around puberty, which was reversed by 14-day treatment with 
tandospirone (Fig. 8). Further, the ability of tandospirone to ameliorate the response of 
lactate production in model animals was abolished by co-administration of WAY-100635, a 
selective 5-HT1A antagonist (Uehara et al., in press).  
These findings are consistent with clinical observations that perospirone and tandospirone 
improved cognitive abilities governed by the PFC, coupled with enhancement of 
electrophysiological activities in this brain region, in patients with schizophrenia (Higuchi et 
al. 2010, Sumiyoshi T. et al. 2009). Translational approach, like this, is expected to provide a 
novel insight into the development of therapeutics targeting cognitive disturbances of 
schizophrenia.  
 
Fig. 8. Extracellular concentrations of lactate in the medial prefrontal cortex in young adult 
rats. Transient blockade of NMDA receptors by MK-801 at the neonatal stage (modeling 
schizophrenia) suppresses lactate increment in response to footshock stress (saline-saline vs. 
MK-801-saline). Treatment with tandospirone, a 5-HT1A partial agonist, for 14 days reverses 
the decrease in lactate production in the model animals (MK-801-saline vs. MK801-
tandospirone. A significant main effect of tandospirone in MK-801-treated animals was 
noted (F(1,8)=12.94, P=0.007 by ANOVA). 
7. Conclusions 
Behavioral, neurochemical and electrophysiological data indicate 5-HT1A agonists improve 
negative symptoms and cognitive deficits of schizophrenia. Specifically, compelling 
evidence suggests that the cognitive benefits of 5-HT1A agonism are mediated by Glu and 
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GABA neurons (Higuchi et al. 2010, Llado-Pelfort et al. 2011). The role for 5-HT1A receptors 
in cognitive enhancement has been suggested by imaging genetics data regarding brain 
energy metabolism (Sumiyoshi T. et al. 2008) and by pharmacogenetics investigations 
(Sumiyoshi T. et al. 2010) [reviewed in (Newman-Tancredi and Kleven 2011, Newman-
Tancredi and Albert in press)]. Findings from translational research, herein presented, are 
expected to facilitate the development of novel therapeutics for cognitive impairment in 
schizophrenia and other psychiatric disorders. 
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